The strength of REALM’s integrated diagnostics approach can be attributed to the world-class businesses that are a part of the corporation. These organizations are centers of excellence in their respective fields and share a commitment to transform healthcare with next-generation solutions.
Ambry Genetics excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Its unparalleled track record of discoveries over 20 years and a growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners enables them to be first to market with innovative products and comprehensive analyses that empower clinicians to confidently inform patient health decisions.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by the company’s industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
Pioneering integrated diagnostics for a new realm of understanding.